Atypical and Classical Forms of the Disease-Associated State of the Prion Protein Exhibit Distinct Neuronal Tropism, Deposition Patterns, and Lesion Profiles  by Kovacs, Gabor G. et al.
The American Journal of Pathology, Vol. 183, No. 5, November 2013ajp.amjpathol.orgIMMUNOPATHOLOGY AND INFECTIOUS DISEASES
Atypical and Classical Forms of the Disease-Associated
State of the Prion Protein Exhibit Distinct Neuronal
Tropism, Deposition Patterns, and Lesion Proﬁles
Gabor G. Kovacs,* Natallia Makarava,y Regina Savtchenko,y and Ilia V. BaskakovyFrom the Institute of Neurology,* Medical University of Vienna, Vienna, Austria; and the Center for Biomedical Engineering and Technology and Department
of Anatomy and Neurobiology,y University of Maryland School of Medicine, Baltimore, MarylandAccepted for publicationC
P
hJuly 9, 2013.
Address correspondence to Ilia
V. Baskakov, Ph.D., Center for
Biomedical Engineering and
Technology, University of
Maryland School of Medicine,
725 W. Lombard St., Baltimore,
MD, 21201. E-mail:
baskakov@umaryland.edu.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.07.024A number of disease-associated PrP forms characterized by abnormally short proteinase Keresistant
fragments (atypical PrPres) were recently described in prion diseases. The relationship between atypical
PrPres and PrPSc, and their role in etiology of prion diseases, remains unknown. We examined the
relationship between PrPSc and atypical PrPres, a form characterized by short C-terminal proteinase
Keresistant fragments, in a prion strain of synthetic origin. We found that the two forms exhibit
distinct neuronal tropism, deposition patterns, and degree of pathological lesions. Immunostaining of
brain regions demonstrated a partial overlap in anatomic involvement of the two forms and revealed the
sites of their selective deposition. The experiments on ampliﬁcation in vitro suggested that distinct
neuronal tropism is attributed to differences in replication requirements, such as preferences for
different cellular cofactors and PrPC glycoforms. Remarkably, deposition of atypical PrPres alone was not
associated with notable pathological lesions, suggesting that it was not neurotoxic, but yet trans-
missible. Unlike PrPSc, atypical PrPres did not show signiﬁcant perineuronal, vascular, or perivascular
immunoreactivity. However, both forms showed substantial synaptic immunoreactivity. Considering
that atypical PrPres is not associated with substantial lesions, this result suggests that not all synaptic
diseaseerelated PrP states are neurotoxic. The current work provides important new insight into our
understanding of the structureepathogenicity relationships of transmissible PrP states. (Am J Pathol
2013, 183: 1539e1547; http://dx.doi.org/10.1016/j.ajpath.2013.07.024)Supported by NIH grants NS045585 and NS074998 (I.V.B.).
G.G.K. and N.M. contributed equally to this work.Prion diseases are a family of transmissible, neurodegener-
ative maladies associated with misfolding and aggregation
of a soluble, cellular isoform of a prion protein (PrPC) into
an abnormal, proteolytically resistant, b-sheeterich iso-
form (PrPSc).1 In classical PrPSc, the region encompassing
approximately residues 90 to 231 is resistant to proteinase K
(PK) digestion and sufﬁcient for prion infectivity.2 In the
past decade, a number of disease-associated PrP forms
characterized by abnormally short PK-resistant fragments
were described in human and animal prion diseases (reviewed
in Tranulis et al3). C-terminal PK-resistant fragments
encompassing residues 154/156 to 231 and 162/167 to 231
were found in a majority of individuals with sporadic
Creutzfeldt-Jakob disease (sCJD).4 A novel sporadic prion
disease referred to as variable protease-sensitive prionopathy
was also accompanied by accumulation of several atypicalstigative Pathology.
.PrP fragments of variable length that were PK resistant.5 In
addition, abnormal PK-resistant fragments were described in
atypical bovine spongiform encephalopathy (BSE), which is
believed to be sporadic in origin,6 and in ovine scrapie.7,8
With the discovery of atypical, disease-associated, PK-
resistant PrP fragments (referred to as atypical PrPres) in
prion diseases of sporadic origin, a number of questions have
been raised. What is a relationship between atypical PrPres
and PrPSc? Are atypical PrPres neurotoxic and transmissible?
Do they play any role in the etiology of sporadic prion
diseases? Although understanding these topics is important
for developing adequate screening and diagnostic tools,
addressing these questions has been difﬁcult because self-
Kovacs et alpropagating PrP states are often present in mixtures, their
properties continue to evolve during serial passages, and
because of the challenges in modeling diseases of sporadic
origin in animal models.9,10
In previous studies, transmissible prion diseases were
induced by inoculating amyloid ﬁbrils produced in vitro
from recombinant PrP.11e16 In wild-type animals, the
diseases triggered by ﬁbrils were characterized by a long,
clinically silent stage and accumulation of atypical PrPres
products,14,15 the features that appeared to be common with
prion diseases of sporadic origin. Remarkably, atypical
PrPres fragments found in animals inoculated with ﬁbrils
were very similar to the C-terminal PK-resistant fragments
found in patients with sCJD or atypical BSE.4,6 Although
atypical PrPres and PrPSc were found to replicate indepen-
dently of each other,15,17 the dynamics in appearance of the
two forms suggested that atypical PrPres was a precursor of
PrPSc.15 Thus, these studies on synthetic prions uncovered
one of the plausible pathways by which PrPSc can emerge.
The current study took advantage of the previously
established system for generating transmissible disease
de novo for examining the relationship between pathogenic
features of the two alternative self-replicating PrP states.
Using synthetic Syrian hamster strain S05, we show that
atypical PrPres and classical PrPSc exhibit distinct neuronal
tropism, deposition patterns, and signiﬁcantly different
severity of pathological lesions. The results of experiments
on ampliﬁcation in vitro suggested that distinct neuronal
tropism could be in part due to differences in replication
requirements of the two states, such as preferences for
different cellular cofactors and PrPC glycoforms. Remark-
ably, deposition of atypical PrPres alone was not associated
with notable pathological lesions, suggesting that this form
was not neurotoxic, but yet transmissible. The current work
provides important new insight into our understanding of
the structureepathogenicity relationship of transmissible
PrP states.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and
Use Committee of the University of Maryland, Baltimore
(Assurance Number A32000-01; Permit Number: 0309001).
Bioassay
Weanling Golden Syrian hamsters (all males) were inocu-
lated intracerebrally under 2% O2/4 MAC (minimum alve-
olar concentration) isoﬂurane anesthesia. In the current
study, animals 1 through 5 or 6 through 8 received 50 mL of
10% brain homogenate (BH) inoculum prepared from1540animal 4 or 7, respectively, from the ﬁrst passage of the
synthetic strain S05.15 After inoculation, hamsters were
observed daily for disease using a blinded scoring protocol.
Hamsters were euthanized as they approached the terminal
stage of the disease. Animals that did not develop clinical
signs or those that did not progress to the terminal stage
were euthanized at 664 days post inoculation (dpi).
For control experiments, animals received 50 mL of 10%
BH inoculum prepared using animals of 661 days of age
(ﬁrst passage), or 10% BH inoculum prepared using animals
inoculated with age-matched control brain materials and
euthanized at 661 dpi (second passage). In addition, another
control animal group received 50 mL of 0.5 mg/mL
recombinant a-PrP.
Histopathological Studies
Formalin-ﬁxed brain halves divided at the midline (hemi-
sphere) were processed for H&E stain, as well as for
immunohistochemistry for PrP, using the mouse mono-
clonal anti-PrP antibody 3F4 (1:1000; Covance, Berkeley,
CA), SAF-84 (1:1000; Cayman Chemical, Ann Arbor, MI),
and antieglial ﬁbrillar acidic protein (GFAP; 1:3000; Dako,
Glostrup, Denmark). Blocks were treated in formic acid
(96%) before embedding in parafﬁn. For detection of
disease-associated PrP, we applied a pretreatment of 30
minutes hydrated autoclaving at 121C followed by 5
minutes in 96% formic acid. We evaluated all tissues for the
presence of inﬂammation and PrP immunoreactivity, and
the brain for the presence of spongiform changes and degree
of gliosis. The degree of spongiform changes, neuronal loss,
and gliosis, and intensity of PrP immunostaining were
semiquantitatively evaluated (0, none; 1, mild; 2, moderate;
and 3, severe), as previously described,13 in the following
anatomical regions: frontal cortex, hippocampus, caudate-
putamen, thalamus, brainstem, and cerebellum. Lesion
proﬁles were obtained for each animal and for animal
groups by averaging scores of spongiform change, neuronal
loss, and gliosis for each anatomical region.
Proteinase K Digestion
Brains were collected aseptically and cut in half with
disposable scalpels. One half was used to prepare 10% BH
in PBS or conversion buffer as described elsewhere,13
whereas the second half was stored at 80C for future
analysis or ﬁxed in formalin for histopathology. For the PK
digestion of BH in sarcosyl, an aliquot of 10% BH was
mixed with an equal volume of 4% sarcosyl in PBS, sup-
plemented with 50 mmol/L Tris (pH 7.5), and digested with
20 mg/mL PK for 30 minutes at 37C with 1000 rpm
shaking using a DELFIA Plateshake plate shaker (Perkin-
Elmer Wallac, Yurku, Finland) placed in a 37C incubator.
PK digestion was stopped by adding SDS sample buffer and
heating the samples for 10 minutes in a boiling water bath.
After loading onto NuPAGE 12% Bis-Tris gels and transferajp.amjpathol.org - The American Journal of Pathology
Table 1 Incubation Time to Disease for Individual Animals
Animal No. Incubation time (days)* Euthanized on day
1 No clinical signsy 664
2 No clinical signsy 664
3 505 664z
4 505 664z
5 393 664z
6 463 588
7 463 588
8 463 664
*Incubation time to ﬁrst clinical signs.
yNo clinical signs for as late as 664 days after inoculation.
zAnimals did not reach terminal stage and were euthanized due to
old age.
Atypical and Classical Prionsto polyvinylidene diﬂuoride membrane, PrP was detected
with 3F4 (epitope 109e112) or SAF-84 (epitope 160e70)
antibody, as indicated. Western blot images were collected
using FluorChem M system (ProteinSimple, Santa Clara,
CA), and density proﬁles were generated using AlphaView
SA software version 3.4.0 (ProteinSimple).
Protein Misfolding Cyclic Ampliﬁcation with Beads
Ten percent normal brain homogenate (NBH) from healthy
hamsters was prepared as described before14 and used as
a substrate for protein misfolding cyclic ampliﬁcation with
beads (PMCAb) assay.18 The sonication program consisted
of 20 seconds sonication pulses delivered at 170 W energy
output applied every 20 minutes during a 24-hour period.
For each subsequent round, 10 mL of the reaction from the
previous round was added to 90 mL of fresh substrate. Each
PMCAb reaction was performed in the presence of three
3/32-inch Teﬂon beads (AmazonSupply, Seattle, WA).
To produce partially deglycosylated substrate, 10% NBH
from healthy hamsters prepared for PMCAb (see above)
was treated with PNGase F (glycerol-free; New England
BioLabs, Ipswich, MA) as follows. After pre-clearance of
NBH at 500  g for 2 minutes, 1500 U/mL PNGase F was
added to the supernatant, the reaction was incubated on
a rotator at 37C for 5 hours, and then, partially deglyco-
sylated NBH was used as a substrate in PMCAb. The
PMCAb format that utilizes partially deglycosylated NBH
is referred to as dgPMCAb. To prepare the RNA-depleted
dgPMCA substrate, 100 mg/mL RNase A (Cat. No.
R4875; Sigma-Aldrich, St. Louis, MO) was added to the
NBH following PNGase F treatment, and the reaction was
incubated on a rotator at 37C for 1 hour as previously
described.19
To analyze production of PK-resistant PrP material in
PMCAb, 10 mL of sample were supplemented with 5 mL of
SDS and 5 mL of PK, to a ﬁnal concentration of 0.25% SDS
and 50 mg/mL PK, followed by incubation at 37C for 1
hour. The digestion was terminated by addition of
SDSesample buffer and heating the samples for 10 minutes
in a boiling water bath. Samples were loaded onto NuPAGE
12% Bis-Tris gels, transferred to polyvinylidene diﬂuoride
membrane, and probed with SAF-84 antibody.
Results
Atypical PrPres and PrPSc Display Different in Vitro
Replication Requirements
Eight animals were examined from the second passage of
the synthetic strain S05 that was produced by inoculating
recombinant PrP amyloid ﬁbrils.15 Depending on the extent
of the disease progression, the eight animals could be
divided into three groups. Animals 1 and 2 (group 1) did not
show any clinical signs of the disease (Table 1). Animals 3,
4, and 5 (group 2) developed clinical signs, but did not reachThe American Journal of Pathology - ajp.amjpathol.orgthe terminal stage of the disease and were euthanized due to
old age (Table 1). Animals 6, 7, and 8 (group 3) developed
clinical signs and progressed to the terminal stage (Table 1).
To detect disease-associated PrP forms, we took advan-
tage of previous studies that showed that PrPSc could be
detected by both 3F4 (epitope 109e112) and SAF-84
(epitope 160e170) antibodies, whereas atypical PrPres
reacts only with SAF-84.14,15,17 Previously, we showed that
PK treatment of atypical PrPres produces three major bands
of approximately 23, 16, and 13 kDa, which correspond to
di-, mono-, and unglycosylated glycoforms of PK-resistant
fragments approximately encompassing residues 152/153
to 231, respectively (Figure 1A).15,17 Because of the overlap
between the di- and monoglycosylated atypical PrPres with
the mono- and unglycosylated PrPSc, respectively, the PK-
resistant proﬁles of brain materials containing mixtures of
atypical PrPres and PrPSc consist of four bands (Figure 1A).
As judged from the PK-resistance proﬁles, atypical
PrPres was predominant in animals 1 and 2, whereas brain
material from animals 3 through 8 showed mixtures of
atypical and PrPSc (Figure 1C). Consistent with the previous
study, atypical PrPres preferred monoglycosylated PrPC,
whereas PrPSc was predominantly diglycosylated15
(Figure 1C). Although animals of all three groups had similar
amounts of atypical PrPres (Figure 1C), animals in group 1
(animals 1 and 2) had very minor amounts of PrPSc, animals in
group 2 (3, 4, and 5) intermediate, and animals in group 3 (6, 7,
and 8) large amounts of PrPSc (Figure 1, B and C).
The following animal groups were examined as negative
controls: uninfected animals euthanized at 661 days of age
(n Z 3); animals inoculated with brain material of aged
animals and euthanized at 559 to 661 dpi (nZ 15); second
passage of brain materials of aged animals euthanized at 526
to 664 dpi (n Z 8); and animals inoculated with recombi-
nant a-PrP and euthanized at 664 dpi (n Z 8). None of the
animals from the control groups developed any clinical
signs nor did they show any PK resistant products on
Western blot analysis (Figure 1E). These control experi-
ments are in good agreement with the results of several
independent negative-control experiments reported in our
previous studies, in which atypical PrPres and PrPSc could1541
Figure 1 Biochemical analysis of brain mate-
rial. A: Schematic representation of the PK-
resistance proﬁles showing an overlap between
atypical PrPres (gray boxes) and PrPSc (black
boxes). B: PK-resistance proﬁles for individual
animals obtained by densitometry of Western blots
stained with SAF-84. Four peaks at 30, 23, 16, and
13 kDa represent six PK-resistant products. C:
Western blots of brain material stained with SAF-
84 and 3F4. D: Analysis of replication require-
ments. PMCAb and dgPMCAb reactions were seeded
with 103-fold diluted brain material containing
a mixture of atypical PrPres and PrPSc, and sub-
jected to three serial rounds in NBH (lanes 3 to 5),
RNA-depleted NBH (lanes 6 to 8), NBH pretreated
with PNGase F (lanes 9 to 11), and RNA-depleted
NBH pretreated with PNGase F (lanes 12 to 14).
Western blot was stained with SAF-84 antibody. E:
Western blots of the following control groups
stained with SAF-84: animals euthanized at 661
days of age (lanes 1 to 3); animals inoculated with
brain material of aged animals and euthanized at
559 to 661 dpi (lanes 4 to 6); second passage of
brain materials of aged animals and euthanized at
526 to 664 dpi (lanes 7 to 9); and animals inoc-
ulated with recombinant a-PrP and euthanized at
664 dpi (lanes 10 to 12). Brain material from
a second passage of S05 is shown as a reference.
Kovacs et albe found only in animals inoculated with recombinant PrP
ﬁbrils.13,15
Experiments using modiﬁed PMCAb that used partially
deglycosylated PrPC as a substrate revealed that atypical
PrPres and PrPSc were different, not only with respect to the
length of their PK-resistant cores, but also with respect to
in vitro ampliﬁcation requirements. PrPSc could be steadily
ampliﬁed only in NBH containing RNA, but not in RNA-
depleted NBH (Figure 1D). In contrast to PrPSc, ampliﬁ-
cation of atypical PrPres was found to be steady regardless
of RNA presence. However, unlike PrPSc, atypical PrPres
could be ampliﬁed only in the modiﬁed PMCAb referred to
as dgPMCAb that used partially deglycosylated PrPC as
a substrate (Figure 1D). The differences in ampliﬁcation
requirements argue that atypical PrPres and PrPSc are two
alternative self-propagating states.The Extent of Brain Lesions Correlates with the Amount
of PrPSc But not Atypical PrPres
Histopathological evaluation revealed spongiform degener-
ation and reactive astrogliosis without any signs of inﬂam-
matory inﬁltration in all animals. However, the extent of
lesions was signiﬁcantly different between the three groups.
In group 1, spongiform changes and reactive gliosis were
very mild (Figure 2, A and D) and largely restricted to the
hippocampus and brainstem (Figure 3A). One animal in this1542group showed mild lesions in the thalamus (Figures 2A and
3A). Minor lesions in animals 1 and 2 were consistent with
the lack of clinical symptoms in this group (Table 1). By
contrast, all three animals in group 3 showed prominent
lesions in the thalamus, caudate-putamen, and brainstem,
and variable involvement of the cortex, hippocampus, and
cerebellum (Figures 2, C and F, and 3A). Animals in group
2 showed intermediate levels of brain lesions, with moderate
lesioning in hippocampus, the caudate-putamen, thalamus,
brainstem, and cortex (Figures 2, B and E, and 3A). Overall,
histopathological assays revealed strong correlation between
the extent of lesions and the amounts of PrPSc, but not
atypical PrPres.Atypical PrPres and PrPSc Displayed Distinct Deposition
Patterns
PrP immunostaining performed with 3F4 and SAF-84
antibody revealed the following types of PrP deposits:
diffuse/synaptic ﬁne deposits, perineuronally accentuated
deposits with somewhat coarser granules surrounding
neuronal perikarya, dot-like deposits in the white matter
(mainly in the cross sections of the corpus callosum), small
granular accumulations on the ependyma, perivascular PrP
aggregates seen also in the vessel walls, and large plaques
and amorphous deposits in the subpial and subependymal
regions (Figure 4). Overall, SAF-84 showed moreajp.amjpathol.org - The American Journal of Pathology
Figure 2 Histopathological analysis of the three groups of animals. AeC: Spongiform change in the frontal cortex (top left images), hippocampus (top
right images), thalamus (bottom left images), and cerebellum (bottom right images). Brain slices were stained with H&E. DeF: Reactive astrogliosis in the
thalamus detected by immunostaining for GFAP. Scale bar: 20 mm (AeC); 15 mm in (DeF).
Atypical and Classical Prionswidespread distribution and labeled more types of PrP
deposits than 3F4, which was consistent with the fact that
SAF-84 stains both atypical and PrPSc, whereas 3F4 reacts
only with PrPSc.
Striking differences in staining patterns between animals
of the three groups were observed (Figures 3, B and C, and
4). Because animals in group 1 showed predominantly
atypical PrPres, detailed comparison of group 1 with groups
2 and 3 revealed differences between the deposition patterns
of atypical PrPres and PrPSc. Lack of perineuronal immu-
noreactivity, and vascular and perivascular deposits in group
1 suggests that unlike PrPSc, atypical PrPres does not have
signiﬁcant afﬁnity to these sites (Figure 4). In group 1,
diffuse synaptic staining in various regions and dot-like
deposits in the white matter were detected with SAF-84,
but not 3F4; therefore, these deposits have to be attributed
to atypical PrPres (Figure 4). This observation argues that
atypical PrPres, like PrPSc, can form synaptic and dot-like
types of deposits. In group 1, subpial and ependymal PrP
deposits were detected with both SAF-84 and with 3F4,
suggesting that these deposits were formed by both atypical
and PrPSc (Figure 4). Subpial and ependymal reactivity
detected by 3F4 in the group could be attributed to minor
amounts of PrPSc found in this group (Figure 1C).
When compared to group 1, animals in groups 2 and 3
showed progressive increases in the amount and intensity
of diffuse/synaptic deposits and subpial and subependymal
plaques (Figure 3, B and C). In addition, perineuronalThe American Journal of Pathology - ajp.amjpathol.orgdeposits and perivascular PrP aggregates appeared in
animals in group 2, and become more pronounced in
animals in group 3. Because the amount of atypical PrPres
was similar for all three groups (Figures 1B and 3D), these
changes have to be attributed to the accumulation of PrPSc.
Atypical PrPres and PrPSc Have Distinct Neuronal
Tropism
Scoring of PrP immunoreactivity using both SAF-84 and
3F4 antibodies revealed progressive increases in the depo-
sition of total PrP in most of the brain regions from group 1
to group 2 and, to a larger extent, group 3, with the ex-
ception of the cerebellum Purkinje layer (Figure 3, BeD).
Such dynamics correlated well with an increase in the
combined amounts of atypical PrPres and PrPSc as analyzed
by Western blot (Figure 1C).
The differences in the neuronal tropism between atypical
PrPres and PrPSc could be illustrated by a comparison of
SAF-84 scoring in group 1, where predominantly atypical
PrPres was found, with that of groups 2 and 3. The cere-
bellum granular layer showed negative immunoreactivity
for SAF-84 in group 1, but a notable increase in groups 2
and 3. This result suggests that atypical PrPres does not
target the cerebellum. On the other hand, the corpus cal-
losum showed relatively high scores for SAF-84 staining in
group 1; this score did not increase in groups 2 and 3 despite
dramatic increases in the amounts of PrPSc in these groups.1543
Figure 3 Comparison of lesion proﬁles and immunoreactivity scores.
Individual lesion proﬁles (A) and the PrP immunoreactivity scores for SAF-
84 (B) and 3F4 (C) antibodies for animals in group 1 (blue), group 2 (red),
and group 3 (black). D: Cumulative lesion score (green) and immunoreac-
tivity scores (SAF-84, blue; 3F4, red) of all examined anatomic regions for
each animal. The subtraction of cumulative 3F4 from SAF-84 immunore-
activity scores reﬂects relative amounts of atypical PrPres (black).
Kovacs et alThis result indicates that atypical PrPres, but not PrPSc, had
high afﬁnity for the corpus callosum. Comparison of 3F4 to
SAF-84 scoring in the groups that contained mixtures of the
two forms (groups 2 and 3) provided additional information1544regarding differential neuronal tropism of atypical PrPres
and PrPSc. Substantially lower scoring by 3F4 than SAF-84
antibody in the frontal upper and deeper layers and hippo-
campus within each of the two groups suggests that these
regions might prefer atypical PrPres over PrPSc. In sum-
mary, although deposition of atypical PrPres and PrPSc were
found to overlap in most brain regions, the cerebellum had
a high afﬁnity for PrPSc, whereas the corpus callosum and,
to a lesser extent, the frontal upper and deeper layers and
hippocampus appeared to have high selectivity for atypical
PrPres.
Discussion
In the current study, two alternative transmissible PrP states,
referred to as atypical PrPres and classical PrPSc, were
found to display partially overlapping neuronal tropisms,
and distinct deposition patterns and pathological lesion
proﬁles within the same host. The lesion proﬁle and PrP
deposition patterns in animals with predominantly atypical
PrPres were found to be remarkably distinct from those with
abundant PrPSc. The extent of brain lesions was found to
correlate well with the amounts of PrPSc, but not atypical
PrPres, in brain. Indeed, accumulation of atypical PrPres
alone did not lead to the signiﬁcant vacuolation and reactive
gliosis that are typically associated with transmissible
spongiform encephalopathies. Moreover, animals in group 1
were asymptomatic. By contrast, the animals in group 2
with an intermediate level of PrPSc developed clinical signs,
but did not reach the terminal stage of the disease for up to
664 days, when they had to be euthanized due to old age.
The animals in group 3 with the largest amounts of PrPSc
progressed to the terminal stage of the diseases. As judged
from the length and position of the PK-resistant region, the
atypical PrPres described here is similar to several
PK-resistant PrP fragments previously observed in human
and animal transmissible spongiform encephalopathies,
including sCJD, atypical BSE, and scrapie.4,6,7
Analysis of region-speciﬁc PrP immunostaining using
3F4 and SAF-84 demonstrated a partial overlap in the
anatomical involvement of PrPSc and atypical PrPres and,
revealed the sites that were selectively targeted by PrPSc
or atypical PrPres. Indeed, the cerebellum accumulated
predominantly PrPSc, whereas the corpus callosum and, to
a lesser extent, the frontal upper and deeper layers and
hippocampus displayed high selectivity for atypical PrPres.
Differences in neuronal tropism could be attributed to the
differences in the biochemical requirements for replication
of the two forms. Consistent with the previous studies, the
PMCAb assay revealed that PrPSc preferred diglycosylated
PrPC as a substrate, whereas atypical PrPres favored mono-
and unglycosylated PrPC molecules. Taking into account
that the ratio of PrPC glycoforms varies in different brain
regions and cell types,20e22 the current work supports the
hypothesis that different brain regions/cell types give selec-
tive advantage to either PrPSc or atypical PrPres, dependingajp.amjpathol.org - The American Journal of Pathology
Figure 4 Analysis of PrP immunoreactivity in the three groups of animals. Representative images of synaptic and perineuronal PrP deposition in thalamus,
ependymal, subpial, and vascular plaques, and the white matter dot-like PrP deposition in the corpus callosum. Relative PrP deposition scores are shown: none
(), mild/focal (þ), or prominent (þþ). Brain slices were immunostained using SAF-84 or 3F4 as indicated. Scale bar Z 30 mm for all panels.
Atypical and Classical Prionson the relative ratio of un-, mono-, and diglycosylated PrPC.
Moreover, differences in the cofactor requirements might
also contribute to selective replication of the two forms by
different brain regions. Regardless of whether RNA plays
a role in prion replication in animal brain, the difference in
RNA dependency of PMCAb ampliﬁcation highlighted
distinct cofactor requirements between atypical PrPres and
PrPSc.
On the basis of the ﬁnding that a strain with longer
incubation times exhibited more widespread PrPSc distri-
bution than a strain with short incubation times, previous
studies suggested that the differences in strain-speciﬁc PrPSc
distribution in brain anatomic regions could be attributed
to differences in incubation times to the disease.23 In the
current study, the animals in group 3 were euthanized at theThe American Journal of Pathology - ajp.amjpathol.orgsame or earlier time points than the animals in group 1, yet
they showed more widespread PrPSc distribution in com-
parison to atypical PrPres. This result argues that the
differences in neuronal tropism between atypical and PrPSc
were not due to differences in animal age.
PrPSc and atypical PrPres were found to display distinct
deposition patterns. Both states were found to form synaptic,
subpial, and ependymal deposits. However, unlike PrPSc,
atypical PrPres did not show signiﬁcant perineuronal, vas-
cular, or perivascular immunoreactivity. In humans, molec-
ular subtypes (strains) of sCJD are characterized by different
anatomic involvement (ie, lesion proﬁles) as well as distinct
immunostaining patterns for disease-associated PrPs.24e26
Although diffuse/synaptic types of deposits appeared in all
sCJD subtypes, plaques or perineuronal immunodeposits1545
Kovacs et alwere more characteristic of cases with type 2 diseasee
associated PrP. Because both synaptic and perineuronal
accumulation of the disease-associated PrP are considered to
impact interneuronal information processing, these deposi-
tions are likely to lead to synaptic/neuronal dysfunction, and
the differences in their distribution and appearance might
result in variable expression of clinical symptoms. Absence
of clinical disease and perineuronal PrP immunoreactivity in
group 1 suggests that this type of deposition is most likely
associated with the neuronal dysfunction. On the other hand,
animals in group 1 showed substantial synaptic immunore-
activity. This observation suggests that the synaptic form of
atypical PrPres might not be as toxic as the synaptic depo-
sition of PrPSc. Reduced toxicity could be due to differences
in the molecular structures of PrPSc and atypical PrPres and/
or absence of the N-terminals and the conserved hydrophobic
domains in atypical PrPres. Interestingly, in previous studies
of human prion diseases, anti-PrP antibodies that recognize
the N-terminal epitopes were found to detect fewer synaptic
deposits than those that react with the central region of PrP.27
Taking into account previous studies on familial forms of
prion disease, PrP deposits with amyloid tinctorial properties
may not necessarily be a reliable marker of TSE trans-
missibility.28 On the other hand, PrP deposits that lack
obvious amyloid tinctorial properties and are localized in the
vicinity of synapses (ie, strategic localization for causing
dysfunction) might represent a transmissible PrP state, but
display little if any neurotoxic effect. In summary, the current
study indicates that not all disease-related PrP forms that
accumulate in the vicinity of synapses are neurotoxic.
In previous studies on generating transmissible prion di-
seases with recombinant PrP ﬁbrils, we proposed that i)
atypical PrPres was the ﬁrst product of PrPC misfolding trig-
gered by recombinant ﬁbrils; ii) deposition of atypical PrPres
represented a clinically silent stage; and iii) atypical PrPres
gave rise to authentic PrPSc, which eventually outcompeted
atypical PrPres.14,15We also showed that despite transmission
within the same host, several serial passages were required to
stabilize a strain-speciﬁc disease phenotype of a synthetic
strain in a manner similar to the phenomenon of prion strain
adaptation that accompanies cross-species transmission.29
Parallel studies on mouse synthetic prions revealed that
a range of transmissible PrPSc states and disease phenotypes
can be generated in mice by inoculating recombinant PrP
ﬁbrils produced in vitro under different solvent condi-
tions.12,30 In a manner similar to evolution of hamster strains,
biochemical and biological properties of synthetic mouse
strains were found to change gradually on serial passaging,
indicative of prion strain adaptation.16,31 Remarkably, serial
passaging led to a convergence of independently produced
mouse strains into a common type.16 Similarly, after several
serial passages, three hamster strains of synthetic origin,
SSLOW, LOTSS, and S05, also showed very similar physi-
cal and biological properties (unpublished observations).
Competitive selection between alternative self-replicating
states was proposed as a possible mechanism responsible1546for convergence of strain phenotypes and adaptation to
a particular replication environment.16
The current work provides new insight into the evolution
of transmissible prion states. First, different self-propagated
states were found to display partially overlapping, yet
different neuronal tropism and deposition patterns. Distinct
neuronal tropism could be attributed to differences in
replication requirements for the two PrP states. Considering
that replacement of atypical PrPres by PrPSc requires several
serial passages, these results could also explain previously
observed ﬁndings that serial transmission of synthetic prions
is accompanied by an apparent change in neurotropism and
involvement of new brain regions.29 Second, deposition of
atypical PrPres alone was found to result in minimal lesions,
which is consistent with our previous studies that atypical
PrPres can propagate and transmit silently.15 Third, the
current ﬁndings illustrate that atypical PrPres and PrPSc
prefer different biochemical environments consistent with
the idea that these two forms are structurally different.
Previously, we proposed that atypical PrPres occasionally
produces PrPSc in seeding events that appeared to be rela-
tively rare and stochastic, and were described by a deformed
templating mechanism.15,32 As soon as the ﬁrst PrPSc
particles were generated, the two self-propagating PrP states
replicated in parallel and competed for the same substrate.
This model explains why full transition from atypical PrPres
to PrPSc might take several years, a time period that in
rodents is equivalent to several serial passages. In addition
to competition for a substrate, atypical PrPres and PrPSc
molecules might also compete for certain synaptic locali-
zations and replication sites. The outcome of the competi-
tion appears to depend on PrPC glycosylation status and the
immediate biochemical environment. A possible therapeutic
intervention could involve interference with PrPSc replica-
tion by an alternative abnormal state that is considerably less
toxic than PrPSc, but capable of self-replicating. Interest-
ingly, a recent study revealed the coexistence of atypical PrP
conformations and PrPSc in a patient with sCJD with
a prolonged clinical course.33 This ﬁnding supports the
concept of possible beneﬁcial effects of alternative self-
replicating PrP states. It would be interesting to determine
in future studies whether atypical PrPres states can interfere
with replication of PrPSc in vivo and whether this approach
could be used as a therapeutic approach for slowing down or
blocking disease progression.
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